Aurobindo Pharma Limited has informed the Exchange about incorporation of CuraTeQ Biologics (Malta) Limited
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has set up a new wholly owned step-down subsidiary called CuraTeQ Biologics (Malta) Limited, incorporated on September 26, 2025. The new entity is fully owned by CuraTeQ Biologics B.V. (Netherlands), which is itself a wholly owned step-down subsidiary of Aurobindo Pharma. The purpose is to expand the company's pharmaceutical products business into Malta. The initial investment is small: EUR 1,200 for 1,200 shares at EUR 1 each, and no regulatory approvals were needed. Promoters and the promoter group have no separate interest in the transaction beyond their holding in the parent company.
This is a routine internal restructuring to support geographic expansion of Aurobindo's biologics business into Europe. The financial impact is negligible given the tiny capital infusion, so it is unlikely to move the stock price on its own but signals continued investment in the biologics segment.